Artigos de revistas sobre o tema "IDO/TDO"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "IDO/TDO".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Oweira, Hani, Imad Lahdou, Stefan Mehrle, Elias Khajeh, Rajan Nikbakhsh, Omid Ghamarnejad, Peter Terness, Christoph Reißfelder, Mahmoud Sadeghi e Ali Ramouz. "Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepG2 Tumor Cells". Journal of Clinical Medicine 11, n.º 16 (16 de agosto de 2022): 4794. http://dx.doi.org/10.3390/jcm11164794.
Texto completo da fonteTerai, Londin, Rochani, Link, Lam, Kaushal, Bhushan, Orloff e Sato. "Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma". Cancers 12, n.º 2 (10 de fevereiro de 2020): 405. http://dx.doi.org/10.3390/cancers12020405.
Texto completo da fonteKim, Chan, Joo Hoon Kim, Jin Sung Kim, Hong Jae Chon e Joo-Hang Kim. "A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): e14228-e14228. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14228.
Texto completo da fonteCampesato, Luis Felipe, Sadna Budhu, Jeremy Tchaicha, Abhinav Jaiswal, Mathieu Gigoux, Stephane Pourpe, Cailian Liu et al. "Blockade of IDO/TDO downstream effectors restricts cancer immune suppression". Journal of Immunology 202, n.º 1_Supplement (1 de maio de 2019): 137.3. http://dx.doi.org/10.4049/jimmunol.202.supp.137.3.
Texto completo da fonteThackray, Sarah J., Christopher G. Mowat e Stephen K. Chapman. "Exploring the mechanism of tryptophan 2,3-dioxygenase". Biochemical Society Transactions 36, n.º 6 (19 de novembro de 2008): 1120–23. http://dx.doi.org/10.1042/bst0361120.
Texto completo da fonteOxenkrug, G. "Genetic and Environmental Impacts in Major Depressive Disorder are Mediated Via Kynurenine Pathway of Tryptophan Metabolism". European Psychiatry 24, S1 (janeiro de 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70899-5.
Texto completo da fonteSUZUKI, Sachiko, Shigenobu TONÉ, Osamu TAKIKAWA, Toshikazu KUBO, Ichiro KOHNO e Yohsuke MINATOGAWA. "Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti". Biochemical Journal 355, n.º 2 (6 de abril de 2001): 425–29. http://dx.doi.org/10.1042/bj3550425.
Texto completo da fonteNienhaus, Karin, e G. Ulrich Nienhaus. "Co Recombination in Human IDO and TDO - A Comparison". Biophysical Journal 106, n.º 2 (janeiro de 2014): 676a. http://dx.doi.org/10.1016/j.bpj.2013.11.3744.
Texto completo da fonteSacramento, Jireh Joy D., e David P. Goldberg. "Oxidation of an indole substrate by porphyrin iron(iii) superoxide: relevance to indoleamine and tryptophan 2,3-dioxygenases". Chemical Communications 56, n.º 20 (2020): 3089–92. http://dx.doi.org/10.1039/c9cc10019a.
Texto completo da fontePaccosi, Sara, Marta Cecchi, Angela Silvano, Sergio Fabbri e Astrid Parenti. "Different effects of tryptophan 2,3-dioxygenase inhibition on SK-Mel-28 and HCT-8 cancer cell lines". Journal of Cancer Research and Clinical Oncology 146, n.º 12 (10 de agosto de 2020): 3155–63. http://dx.doi.org/10.1007/s00432-020-03351-2.
Texto completo da fonteFunakoshi, Hiroshi, Masaaki Kanai e Toshikazu Nakamura. "Modulation of Tryptophan Metabolism, Promotion of Neurogenesis and Alteration of Anxiety-Related Behavior in Tryptophan 2,3-Dioxygenase-Deficient Mice". International Journal of Tryptophan Research 4 (janeiro de 2011): IJTR.S5783. http://dx.doi.org/10.4137/ijtr.s5783.
Texto completo da fonteBadawy, Abdulla A.-B. "Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects". International Journal of Tryptophan Research 10 (1 de janeiro de 2017): 117864691769193. http://dx.doi.org/10.1177/1178646917691938.
Texto completo da fonteYoshioka, Saeko, Tomonori Ikeda, Sogo Fukuchi, Yurika Kawai, Katsumi Ohta, Hisashi Murakami, Naohisa Ogo, Daisuke Muraoka, Osamu Takikawa e Akira Asai. "Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase". International Journal of Tryptophan Research 15 (janeiro de 2022): 117864692211384. http://dx.doi.org/10.1177/11786469221138456.
Texto completo da fonteBadawy, Abdulla A.-B., e Gilles J. Guillemin. "Species Differences in Tryptophan Metabolism and Disposition". International Journal of Tryptophan Research 15 (janeiro de 2022): 117864692211225. http://dx.doi.org/10.1177/11786469221122511.
Texto completo da fonteYeh, Syun-Ru, Ariel Lewis-Ballester e Shay Karkashon. "Comparative Studies of Human Indoleamine 2,3-Dioxygenase (IDO) and Tryptophan Dioxygenase (TDO)". Biophysical Journal 102, n.º 3 (janeiro de 2012): 467a. http://dx.doi.org/10.1016/j.bpj.2011.11.2560.
Texto completo da fonteTakkenkamp, Tim J., Mathilde Jalving, Frederik J. H. Hoogwater e Annemiek M. E. Walenkamp. "The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors". Endocrine-Related Cancer 27, n.º 9 (setembro de 2020): R329—R343. http://dx.doi.org/10.1530/erc-20-0113.
Texto completo da fonteLuques, Lisandro, Ashby Kissoondoyal, Emily De Sousa, Paula Quaglietta, David Malkin, Stefano Cairo, Emilie Indersie e Reto Baertschiger. "Abstract 3539: Indoleamine-2,3-dioxygenase 2 (IDO-2) is expressed in hepatoblastoma cells and associated with metastatic state". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 3539. http://dx.doi.org/10.1158/1538-7445.am2023-3539.
Texto completo da fonteQin, Yanjie, Nanxi Wang, Xinlin Zhang, Xuemei Han, Xuejia Zhai e Yongning Lu. "IDO and TDO as a potential therapeutic target in different types of depression". Metabolic Brain Disease 33, n.º 6 (16 de julho de 2018): 1787–800. http://dx.doi.org/10.1007/s11011-018-0290-7.
Texto completo da fonteMuzik, O., F. John, S. Mittal e C. Juhasz. "P11.35 Fluorine-18-labeled PET radiotracers for imaging tryptophan uptake and metabolism in brain tumors". Neuro-Oncology 21, Supplement_3 (agosto de 2019): iii50—iii51. http://dx.doi.org/10.1093/neuonc/noz126.181.
Texto completo da fonteYe, Zixiang, Linxiu Yue, Jiachen Shi, Mingmei Shao e Tao Wu. "Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications". Journal of Cancer 10, n.º 12 (2019): 2771–82. http://dx.doi.org/10.7150/jca.31727.
Texto completo da fonteJovanovic, Filip, Kenneth D. Candido e Nebojsa Nick Knezevic. "The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents". International Journal of Molecular Sciences 21, n.º 17 (22 de agosto de 2020): 6045. http://dx.doi.org/10.3390/ijms21176045.
Texto completo da fonteNaismith, James H. "Tryptophan oxygenation: mechanistic considerations". Biochemical Society Transactions 40, n.º 3 (22 de maio de 2012): 509–14. http://dx.doi.org/10.1042/bst20120073.
Texto completo da fonteAshoura, Norah E., Joseph D. Dekker, Todd Triplett, Kendra Garrison, John Blazeck, Christos Karamitros, Candice Lamb et al. "The Force Awakens: Illuminating the role of kynurenine in cancer progression and treatment." Journal of Immunology 200, n.º 1_Supplement (1 de maio de 2018): 177.3. http://dx.doi.org/10.4049/jimmunol.200.supp.177.3.
Texto completo da fonteRafice, Sara A., Nishma Chauhan, Igor Efimov, Jaswir Basran e Emma Lloyd Raven. "Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase". Biochemical Society Transactions 37, n.º 2 (20 de março de 2009): 408–12. http://dx.doi.org/10.1042/bst0370408.
Texto completo da fonteBadawy, Abdulla A.-B., e Gilles Guillemin. "The Plasma [Kynurenine]/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal". International Journal of Tryptophan Research 12 (janeiro de 2019): 117864691986897. http://dx.doi.org/10.1177/1178646919868978.
Texto completo da fonteOh, Angela. "Crystallization of heme dioxygenases IDO and TDO facilitates structure-based design of cancer immunology therapeutics". Acta Crystallographica Section A Foundations and Advances 76, a1 (2 de agosto de 2020): a45. http://dx.doi.org/10.1107/s0108767320099547.
Texto completo da fonteCampesato, Luis Felipe, Sadna Budhu, Jeremy Tchaicha, Stephane Pourpe, Cailian Liu, Mark G. Manfredi, Karen McGovern, Jedd D. Wolchok e Taha Merghoub. "Interaction between Kynurenine and the AhR is an effector mechanism of tumor immunosuppression and represents a potential immunotherapy target". Journal of Immunology 200, n.º 1_Supplement (1 de maio de 2018): 177.5. http://dx.doi.org/10.4049/jimmunol.200.supp.177.5.
Texto completo da fonteAlan, Wise, Mcguinness E. Barry, Cowley M. Phillip, Trewick C. Sarah, Bevan Nicola, Szybut Clare e Brown J. Thomas. "ITOC2 – 013. In vitro kynurenine modulation by novel dual-acting and selective TDO and IDO inhibitors". European Journal of Cancer 51 (março de 2015): S5. http://dx.doi.org/10.1016/j.ejca.2015.01.026.
Texto completo da fonteYuasa, Hajime J., e Helen J. Ball. "Efficient tryptophan-catabolizing activity is consistently conserved through evolution of TDO enzymes, but not IDO enzymes". Journal of Experimental Zoology Part B: Molecular and Developmental Evolution 324, n.º 2 (20 de fevereiro de 2015): 128–40. http://dx.doi.org/10.1002/jez.b.22608.
Texto completo da fonteBadawy, Abdulla A. B., Aryan M. A. Namboodiri e John R. Moffett. "The end of the road for the tryptophan depletion concept in pregnancy and infection". Clinical Science 130, n.º 15 (29 de junho de 2016): 1327–33. http://dx.doi.org/10.1042/cs20160153.
Texto completo da fonteEl-Zahabi, Mohamed Ayman ALy, Mostafa Youssef Abouzeid, Ibrahim H. Eissa e Mohamed S. Taghour. "DUAL INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) AND TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AS ANTI-TUMOR IMMUNE MODULATORS". Al-Azhar Journal of Pharmaceutical Sciences 69, n.º 1 (1 de março de 2024): 38–61. http://dx.doi.org/10.21608/ajps.2024.360357.
Texto completo da fonteKim, C., N. K. Lee, J. S. Kim, W. R. Kim, D. H. Kim, D. J. Kim, J. S. Oh, S. K. Chang, J. W. Kim e H. J. Chon. "An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade". Annals of Oncology 29 (outubro de 2018): viii416. http://dx.doi.org/10.1093/annonc/mdy288.039.
Texto completo da fonteLiu, Xiangdong, Niu Shin, Holly K. Koblish, Gengjie Yang, Qian Wang, Kathy Wang, Lynn Leffet et al. "Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity". Blood 115, n.º 17 (29 de abril de 2010): 3520–30. http://dx.doi.org/10.1182/blood-2009-09-246124.
Texto completo da fonteBrincks, Erik L., James Adams, Lifu Wang, Benjamin Turner, Agnieszka Marcinowicz, Jiyuan Ke, Michael Essmann et al. "Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1". Oncotarget 11, n.º 25 (23 de junho de 2020): 2438–61. http://dx.doi.org/10.18632/oncotarget.27646.
Texto completo da fonteBerthon, Céline, Michaela Fontenay, Selim Corm, Isabelle Briche, Michel Lhermitte e Bruno Quesnel. "Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification". Blood 120, n.º 21 (16 de novembro de 2012): 3843. http://dx.doi.org/10.1182/blood.v120.21.3843.3843.
Texto completo da fontePetrovic, Vladimir, Jamie Wong, Cedric E. Dos Santos, Richard Smith, Dan Fitzpatrick, Robert Loberg e Ariel Avilion. "IDO Pathway Analysis for Identifying Novel Biomarkers in Multiple Myeloma". Blood 132, Supplement 1 (29 de novembro de 2018): 5572. http://dx.doi.org/10.1182/blood-2018-99-111392.
Texto completo da fonteBooth, Nicholas, Wells Brockbank, Samuel Oh e Karl Kingsley. "Indoleamine 2,3-dioxygenase (IDO) and tryptophan dioxygenase (TDO) mRNA expression in oral squamous cell carcinoma cells is actively and differentially modulated". Journal of Molecular Pathophysiology 1, n.º 1 (2012): 29. http://dx.doi.org/10.5455/jmp.20120609040915.
Texto completo da fonteChen, Xiangli, Yuzhu Zang, Dujuan Li, Jianmin Guo, Yacai Wang, Yuqi Lin e Zhenghong Wei. "IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era". Medicine 99, n.º 21 (22 de maio de 2020): e19883. http://dx.doi.org/10.1097/md.0000000000019883.
Texto completo da fonteStone, Trevor W., e Richard O. Williams. "Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation–Cancer Interface". Cancers 15, n.º 11 (24 de maio de 2023): 2895. http://dx.doi.org/10.3390/cancers15112895.
Texto completo da fonteJovanovic, Filip, Aboorva Sudhakar e Nebojsa Nick Knezevic. "The Kynurenine Pathway and Polycystic Ovary Syndrome: Inflammation as a Common Denominator". International Journal of Tryptophan Research 15 (janeiro de 2022): 117864692210992. http://dx.doi.org/10.1177/11786469221099214.
Texto completo da fonteNoakes, Rowland R. "Effects of Tranilast on the Urinary Excretion of Kynurenic and Quinolinic Acid under Conditions of L Tryptophan Loading". International Journal of Tryptophan Research 6 (janeiro de 2013): IJTR.S12797. http://dx.doi.org/10.4137/ijtr.s12797.
Texto completo da fonteKubacka, Justyna, Anna Stefańska e Grażyna Sypniewska. "Kynurenine pathway: the link between depressive disorders and inflammation". Postępy Higieny i Medycyny Doświadczalnej 74 (6 de agosto de 2020): 331–39. http://dx.doi.org/10.5604/01.3001.0014.3454.
Texto completo da fonteSpector, Sydney, Chunjing Wu, Dan Nguyen, George Theodore, Ashley Garcia, Lynn Feun, Niramol Savaraj e Medhi Wangpaichitr. "Abstract 2325: Targeting kynurenine pathway using novel IDO/TDO dual inhibitor (AT0174) to modulate tumor microenvironment in platinum resistant non-small cell lung cancer cancer: An immunometabolism compliment markers". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 2325. http://dx.doi.org/10.1158/1538-7445.am2022-2325.
Texto completo da fontePal, Anasua, Philipp Zimmer, Dorothea Clauss, Martina E. Schmidt, Cornelia M. Ulrich, Joachim Wiskemann e Karen Steindorf. "Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients". International Journal of Sports Medicine 42, n.º 01 (24 de julho de 2020): 33–40. http://dx.doi.org/10.1055/a-1186-1009.
Texto completo da fonteGiannakis, Marios, Haoxin Li, Chelsea Jin, Shuba Gopal, Kaushal Desai, Christine Horak, Megan Wind-Rotolo et al. "Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients." Journal of Clinical Oncology 35, n.º 15_suppl (20 de maio de 2017): 3036. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3036.
Texto completo da fontePires, Ananda Staats, Shabarni Gupta, Sean A. Barton, Roshana Vander Wall, Vanessa Tan, Benjamin Heng, Jacqueline K. Phillips e Gilles J. Guillemin. "Temporal Profile of Kynurenine Pathway Metabolites in a Rodent Model of Autosomal Recessive Polycystic Kidney Disease". International Journal of Tryptophan Research 15 (janeiro de 2022): 117864692211260. http://dx.doi.org/10.1177/11786469221126063.
Texto completo da fontePapadopoulos, Kyriakos, Michael Cecchini, Juanita S. Lopez, Dirk Jäger, Ki Young Chung, Michael Platten, Florian Prinz et al. "Abstract CT276: Preliminary analysis of pharmacokinetic (PK) and target engagement biomarkers from a first in human phase 1 study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): CT276. http://dx.doi.org/10.1158/1538-7445.am2023-ct276.
Texto completo da fonteDawood, Shazia, Samina Bano e Abdulla Abu-Bakr Badawy. "Inflammation and serotonin deficiency in major depressive disorder: Molecular docking of antidepressant and antiinflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases". Bioscience Reports, 4 de maio de 2022. http://dx.doi.org/10.1042/bsr20220426.
Texto completo da fonteGualdoni, Gisela S., Patricia V. Jacobo, Cristian M. Sobarzo, Cecilia V. Pérez, María E. Matzkin, Christian Höcht, Mónica B. Frungieri et al. "Role of indoleamine 2,3-dioxygenase in testicular immune-privilege". Scientific Reports 9, n.º 1 (4 de novembro de 2019). http://dx.doi.org/10.1038/s41598-019-52192-8.
Texto completo da fonteOxenkrug, Gregory, e Valeriya Navrotska. "Extension of life span by down-regulation of enzymes catalyzing tryptophan conversion into kynurenine: Possible implications for mechanisms of aging". Experimental Biology and Medicine, 10 de junho de 2023, 153537022311794. http://dx.doi.org/10.1177/15353702231179411.
Texto completo da fonte